Literature DB >> 8254735

Inhibition of human immunodeficiency virus type 1 Tat-dependent activation of translation in Xenopus oocytes by the benzodiazepine Ro24-7429 requires trans-activation response element loop sequences.

M Braddock1, P Cannon, M Muckenthaler, A J Kingsman, S M Kingsman.   

Abstract

Two benzodiazepine compounds, [7-chloro-5-(2-pyrryl)-3H-1,4 benzodiazapin-2-(H)-one] (Ro5-3335) and [7-chloro-5-(1H-pyrrol-2-yl)-3H-benzo[e] [1,4] diazepin-2-yl]- methylamine (Ro24-7429), inhibit human immunodeficiency virus type 1 (HIV-1) replication via a specific effect on the function of the transactivator protein, Tat. To gain further insight into the mechanism of action of these compounds, we have tested their effects in an alternative assay for Tat activation in Xenopus oocytes. In this system, translation of trans-activation response element (TAR)-containing RNA is activated by Tat. Both compounds specifically blocked activation of translation in a dose-dependent fashion, with Ro24-7429 showing the greater potency. In the Xenopus oocyte system, as in mammalian cells, mutation of the TAR loop sequences abolishes Tat action. However, it is possible to obtain TAR-specific, Tat-dependent activation of a target RNA with a mutation in the loop provided that this target is in large excess. This result has been interpreted as indicating that a negative factor has been titrated (M. Braddock, R. Powell, A.D. Blanchard, A.J. Kingsman, and S.M. Kingsman, FASEB J. 7:214-222, 1993). Interestingly Ro24-7429 was unable to inhibit the TAR-specific but loop sequence-independent mode of translational activation. This finding suggests that a specific loop-binding cellular factor may mediate the effects of this inhibitor of Tat action. Consistent with this notion, we could not detect any effect of Ro24-7429 on the efficiency of specific Tat binding to TAR in vitro.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8254735      PMCID: PMC236260     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  A nuclear translational block imposed by the HIV-1 U3 region is relieved by the Tat-TAR interaction.

Authors:  M Braddock; A M Thorburn; A Chambers; G D Elliott; G J Anderson; A J Kingsman; S M Kingsman
Journal:  Cell       Date:  1990-09-21       Impact factor: 41.582

2.  Fragments of the HIV-1 Tat protein specifically bind TAR RNA.

Authors:  K M Weeks; C Ampe; S C Schultz; T A Steitz; D M Crothers
Journal:  Science       Date:  1990-09-14       Impact factor: 47.728

3.  Trans-activation by HIV-1 Tat via a heterologous RNA binding protein.

Authors:  M J Selby; B M Peterlin
Journal:  Cell       Date:  1990-08-24       Impact factor: 41.582

4.  Autoradiography using storage phosphor technology.

Authors:  R F Johnston; S C Pickett; D L Barker
Journal:  Electrophoresis       Date:  1990-05       Impact factor: 3.535

5.  Activation of transcription by HIV-1 Tat protein tethered to nascent RNA through another protein.

Authors:  C Southgate; M L Zapp; M R Green
Journal:  Nature       Date:  1990-06-14       Impact factor: 49.962

6.  A cDNA for a protein that interacts with the human immunodeficiency virus Tat transactivator.

Authors:  P Nelbock; P J Dillon; A Perkins; C A Rosen
Journal:  Science       Date:  1990-06-29       Impact factor: 47.728

7.  Regulation of mRNA accumulation by a human immunodeficiency virus trans-activator protein.

Authors:  M A Muesing; D H Smith; D J Capon
Journal:  Cell       Date:  1987-02-27       Impact factor: 41.582

8.  HIV-1 tat trans-activation requires the loop sequence within tar.

Authors:  S Feng; E C Holland
Journal:  Nature       Date:  1988-07-14       Impact factor: 49.962

9.  Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives.

Authors:  R Pauwels; K Andries; J Desmyter; D Schols; M J Kukla; H J Breslin; A Raeymaeckers; J Van Gelder; R Woestenborghs; J Heykants
Journal:  Nature       Date:  1990-02-01       Impact factor: 49.962

10.  The type 1 human immunodeficiency virus Tat binding protein is a transcriptional activator belonging to an additional family of evolutionarily conserved genes.

Authors:  B Ohana; P A Moore; S M Ruben; C D Southgate; M R Green; C A Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-01       Impact factor: 11.205

View more
  7 in total

1.  Inhibitors of human immunodeficiency virus type 1 reverse transcriptase target distinct phases of early reverse transcription.

Authors:  C W Hooker; W B Lott; D Harrich
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Inhibition of human immunodeficiency virus type 1 replication in acutely and chronically infected cells by EM2487, a novel substance produced by a Streptomyces species.

Authors:  M Baba; M Okamoto; H Takeuchi
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

3.  Resistance of chimpanzee T cells to human immunodeficiency virus type 1 Tat-enhanced oxidative stress and apoptosis.

Authors:  A Ehret; M O Westendorp; I Herr; K M Debatin; J L Heeney; R Frank; P H Krammer
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

4.  Tat-independent replication of human immunodeficiency viruses.

Authors:  L Luznik; G Kraus; J Guatelli; D Richman; F Wong-Staal
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

5.  An autoregulated dual-function antitat gene for human immunodeficiency virus type 1 gene therapy.

Authors:  J Lisziewicz; D Sun; B Trapnell; M Thomson; H K Chang; B Ensoli; B Peng
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

6.  Cooperation between herpes simplex virus type 1-encoded ICP0 and Tat to support transcription of human immunodeficiency virus type 1 long terminal repeat in vivo can occur in the absence of the TAR binding site.

Authors:  S L Schafer; J Vlach; P M Pitha
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

7.  Strategies to Block HIV Transcription: Focus on Small Molecule Tat Inhibitors.

Authors:  Guillaume Mousseau; Susana Valente
Journal:  Biology (Basel)       Date:  2012-11-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.